louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05189873: GnRH Agonist Plus Hormone Replacement Therapy vs Hormone Replacement Therapy on IVF Outcomes
Official title: Comparison of the Pregnancy Outcomes in Patients With the Polycystic Ovarian Syndrome in Two Endometrial Preparation Method GnRH Agonist Plus Hormone Replacement Therapy Versus Hormone Replacement Therapy in Frozen Embryo Transfer Cycle
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Polycystic Ovary Syndrome
Infertility, Female
Lead sponsor: Tehran University of Medical Sciences
Sponsor class: OTHER
First posted: 2022-01-13
Enrollment: 128
Sex: FEMALE
Minimum age (years): 20
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The study is conducted at Arash Women's Hospital on all women undergoing the frozen embryo transfer cycle. Patients who signed informed consent will be randomly divided into two groups. The first group will receive GnRH agonist plus hormone replacement therapy for endometrial preparation. Group 2 will receive hormone replacement therapy. The random allocation and final outcome of the study will be assessed by a person who is unaware of the study process. Also, the statistician will be unaware of the study process


Eligibility criteria: Inclusion Criteria:

The first or second cycle of embryo transfer Normal uterine cavity PCO diagnosis based on Rotterdam criteria and correction (2018) Age 20 to 40 years

Exclusion Criteria:

Infertility with severe male factor endometriosis immunological disease FSH higher than 10 BMI greater than or equal to 30 Endometrial thickness on the day of transfer is less than 7 mm History of recurrent miscarriage

Primary outcomes:
measure: Endometrial thickness
timeFrame: On the day of transfer
measure: Chemical pregnancy
timeFrame: 14 days after transfer
measure: Clinical pregnancy
timeFrame: 12 weeks of pregnancy
Secondary outcomes:
Other outcomes:
Locations:
city: Tehran
country: Iran, Islamic Republic of
facility: Arash women's hospital,Tehran university of medical sciences
Study officials:
affiliation: Tehran University of Medical Sciences
name: Ashraf Moini, professor
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02782273: Morphine Versus Ketorolac in Renal Colic
Official title: The Analgesic Effects of Morphine Versus Ketorolac in Renal Colic
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Renal Colic
Keywords: ketorolac
pain relieve
morphine
Lead sponsor: Bucharest Emergency Hospital
Sponsor class: OTHER
First posted: 2016-05-25
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The study is prospective, double blinded, randomised controlled and has the purpose to compare the analgesic effects of ketorolac or morphine intravenous in renal colic.

Detailed description: The study will take place in the Emergency Department of the Clinical Emergency Hospital Bucharest and will compare the analgesic effects of ketorolac tromethamine against morphine in renal colic.

The patients will be randomised to receive either ketorolac 30 mg intravenous (diluted in 20 ml of 0,9% saline) or morphine 0,1 mg/kg weight intravenous. A scale of 1-10 will be used for measuring the pain, and the effects of the treatment will be evaluated at 15 minutes and 30 minutes from the administration of the drugs. After 30 minutes if there is no significant reduction of the pain a rescue therapy will be used : chlorhydrate drotaverine 40 mg, xilocaine 100 mg, both diluted in 100 ml saline and the other medication not used from the study (morphine or ketorolac tromethamine).

Eligibility criteria: Inclusion Criteria:

* clinical diagnosis of renal colic
* grade 5 pain on a 1-10 visual pain scale

Exclusion Criteria:

* contraindications of ketorolac or opioids
* pregnancy
* allergies to ketorolac or opioids
* refusal of participation

Primary outcomes:
measure: Reducing the grade of pain
timeFrame: 15 minutes, 30 minutes
Secondary outcomes:
measure: Time of staying in emergency department
timeFrame: 30 minutes, 1 hour, 2 hours
measure: The necessity of urology consult - interventional measures
timeFrame: 7 days
measure: The cost of each treatment
timeFrame: 1 hour
measure: The necessity to use rescue therapy - pain > 5 grade
timeFrame: 30 minutes
measure: Side effects of each treatment
timeFrame: 30 minutes
Other outcomes:
Locations:
Study officials:
affiliation: Clinical Emergency Hospital Bucharest
name: Dan Marinescu, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02528773: Efficacy of ART to Interrupt HIV Transmission Networks
Official title: Efficacy of ART to Interrupt HIV Transmission Networks
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: HIV
Lead sponsor: University of California, San Diego
Sponsor class: OTHER
First posted: 2015-08-19
Enrollment: 256
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Persons with newly diagnosed HIV infection

Brief summary: The investigators are conducting a study to learn more about the spread of HIV infection within different geographic regions and populations in San Diego County, with the goal of demonstrating that early use of HIV treatment can reduce the number of new infections in our community. At the study visits, participants will be examined by the study staff and asked to donate some blood. Participants will also be asked several questions about themselves, their background, behaviors, health, and the general geographic area in which they live. By collecting information about antiretroviral treatment choices that are made by study participants, the investigators will be better able to measure how effectively HIV treatment can interrupt (i.e., block) the spread of HIV. All of the information gathered at the study visits will be de-identified and analyzed. Study staff will use the information to better understand in which groups of people, and in what areas of San Diego, HIV is spreading most quickly. This information will be used to determine how well Antiretroviral Therapy (HIV treatment) by certain individuals can control the spread of HIV within the population.


Eligibility criteria: Inclusion Criteria:

1. Age ≥18 years of age
2. Newly diagnosed HIV infection
3. ART naïve (≤7 days ART, previous use of PEP or PrEP are not exclusions)
4. Subject must be able to provide written consent
5. Subject must agree to study specific specimen collections and visit schedule.
6. Subjects with newly diagnosed HIV infection who were identified on or after May 1, 2014 will be eligible for enrollment as long as they are co-enrolled to either AEH020 (project 08-0278) or AEH030 (project 140093) and DID meet the above study inclusion criteria (items at the time of enrollment to protocols AEH020 or AEH030).

Exclusion Criteria:

1. Any factor or factors that in the opinion of the local investigator that could prevent compliance with study requirements.
2. Contraindication to phlebotomy or specimen collection.

Primary outcomes:
measure: Network-level efficacy of ART as measured by the number of newly infected persons and network cluster growth over time
timeFrame: 5 Years
Secondary outcomes:
Other outcomes:
Locations:
city: San Diego
country: United States
facility: UCSD AntiViral Research Center
state: California
Study officials:
affiliation: UCSD
name: Susan J Little, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01272973: Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NN9924 in Healthy Male Subjects
Official title: Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of a Long-acting GLP-1 Analogue in Healthy Male Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Diabetes
Diabetes Mellitus, Type 2
Healthy
Lead sponsor: Novo Nordisk A/S
Sponsor class: INDUSTRY
First posted: 2011-01-10
Enrollment: 96
Sex: MALE
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This trial is conducted in Europe. The aim of the trial is to investigate safety, tolerability, pharmacokinetics (the rate at which the body eliminates the trial drug) and pharmacodynamics (the effect of the investigated drug on the body) of NN9924 in healthy male subjects


Eligibility criteria: Inclusion Criteria:

* Healthy male subjects, based on an assessment of medical history, physical examination and
* BMI between 21 and 30 kg/m2 (21 inclusive)

Exclusion Criteria:

* Male subjects who are sexually active and unwilling to use a highly effective method of contraception for both them and their nonpregnant partner
* Any clinically significant, abnormal disease history of the following systems: cardio-pulmonary, gastrointestinal, hepatic, neurological, renal,genitourinary, endocrine or haematological
* The receipt of any investigational product within 90 days before screening, or is currently enrolled in any other clinical trial

Primary outcomes:
measure: Frequency of adverse events (AEs)
timeFrame: from the first trial related activity (screening visit) and until completion of the post treatment follow-up visit 91-105 days after first dose
Secondary outcomes:
measure: Hypoglycaemic episodes
timeFrame: from the first trial related activity (screening visit) and until completion of the post treatment follow-up visit 91-105 days after first dose
measure: Laboratory safety variables (haematology, biochemistry, and urinalysis)
timeFrame: from the first trial related activity (screening visit) and until completion of the post treatment follow-up visit 91-105 days after first dose
measure: Maximum plasma concentration of NN9924
timeFrame: after dosing on the 68th, 69th and 70th Day
measure: Area under the plasma concentration curve over the dosing interval (0-24 hours)
timeFrame: after dosing on the 68th, 69th and 70th day
measure: Terminal phase elimination half-life
timeFrame: from last dose (day 70) to follow-up visit 91-105 days after first dose
Other outcomes:
Locations:
city: Berlin
country: Germany
Study officials:
affiliation: Novo Nordisk A/S
name: Global Clinical Registry (GCR, 1452)
role: STUDY_DIRECTOR
References:
Clinical trial NCT01109173: Confirmatory Study Nepafenac 0.3%
Official title: Clinical Evaluation of Nepafenac Ophthalmic Suspension, 0.3% for Prevention and Treatment of Ocular Inflammation and Pain After Cataract Surgery
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Cataract
Lead sponsor: Alcon Research
Sponsor class: INDUSTRY
First posted: 2010-04-23
Enrollment: 2120
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study was to assess the safety and efficacy of an investigational eye drop intended for the prevention and treatment of inflammation (swelling and redness) and pain in the eye after cataract extraction.


Eligibility criteria: Inclusion Criteria:

* Planned cataract extraction by phacoemulsification with the implantation of a posterior chamber intraocular lens;
* Patients who, in the opinion of the Investigator, would have improvement in best-corrected visual acuity after surgery;
* Able to understand and sign an informed consent;
* Other protocol-defined inclusion criteria may apply.

Exclusion Criteria:

* Use of topical ocular, inhaled or systemic nonsteroidal anti-inflammatory drugs within 7 days of surgery, with the exception of the allowed low dose of aspirin (up to 100 mg) prior to surgery and through study exit;
* Use of topical ocular, inhaled or systemic steroids within 14 days prior to surgery and through study exit;
* History of chronic or recurrent inflammatory eye disease (eg, iritis, scleritis, uveitis, iridocyclitis, rubeosis iridis) in the operative eye;
* Diabetic retinopathy in the operative eye;
* Known or suspected allergy or hypersensitivity to non-steroidal anti-inflammatory drugs (NSAIDs), or to any component of the test article;
* Other protocol-defined exclusion criteria may apply.

Primary outcomes:
measure: Percentage of Patients Cured at Day 14
timeFrame: Day 14
Secondary outcomes:
measure: Percentage of Patients Pain-Free at Day 14
timeFrame: Day 14
Other outcomes:
Locations:
city: Fort Worth
country: United States
facility: Contact Alcon Call Center For Trial Locations
state: Texas
Study officials:
affiliation: Alcon Research
name: Dana Sager, MS
role: STUDY_DIRECTOR
References:
Clinical trial NCT03434873: Effect of Motor Cortex Versus Sacral Magnetic Stimulation in Multiple Sclerosis Patients With Urinary Tract Dysfunction
Official title: Effect of Motor Cortex Magnetic Stimulation Versus Sacral Magnetic Stimulation in Lower Urinary Tract Dysfunction in Multiple Sclerosis Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Multiple Sclerosis
Lower Urinary Tract Symptoms
Keywords: magnetic stimulation, multiple sclerosis
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2018-02-15
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This work is intended to assess the effect of repetitive magnetic stimulation on the sacral roots versus repetitive magnetic stimulation on motor cortex in multiple sclerosis patients with the lower urinary tract dysfunction.

Detailed description: Twenty Multiple sclerosis patients with lower urinary tract symptoms will be receiving repetitive magnetic stimulation on sacral roots. Another twenty Multiple sclerosis patient with lower urinary tract symptoms will be receiving repetitive magnetic stimulation on motor cortex. Treatment outcome will be assessed and compared between the two groups.

Twenty trains of 50 stimuli at 5 Hz (train duration: 10 seconds) separated by a 40-second pause were delivered for a total of 1000 pulses (total duration: 16 minutes) once a day for four consecutive days for two weeks.

Eligibility criteria: Inclusion Criteria:

* Multiple Sclerosis patients (diagnosed by McDonald criteria 2010) with lower urinary tract dysfunction
* Adults more than 18 years
* Unresponsiveness to medical treatment
* Urodynamic diagnosis of detrusor overactivity and/or detrusor underactivity and/or detrusor-sphincter dyssynergia

Exclusion Criteria:

* Urinary tract infections
* Pregnancy

Primary outcomes:
measure: Change from baseline King's Health QoL questionnaire score after treatment
timeFrame: 1-7 days after treatment
measure: Change from baseline Post-void residual urine after treatment
timeFrame: 1-7 days after treatment
measure: Change from baseline Maximum Cystometric Capacity (MCC) after treatment
timeFrame: 1-7 days after treatment
measure: Change from baseline Maximum Flow Rate (Qmax) after treatment
timeFrame: 1-7 days after treatment
measure: Change from baseline Detrusor pressure at maximum flow rate (Pdet @Qmax) after treatment
timeFrame: 1-7 days after treatment
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT06701773: Computational Fluid Dynamics Predicting Intraprosthetic Thrombus Formation and Progression Following EVAR
Official title: Computational Fluid Dynamics Predicting Intraprosthetic Thrombus Formation and Progression Following Endovascular Aortic Repair: a Two-center Retrospective Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Intraprosthetic Thrombus
Limb Graft Occlusion
Lead sponsor: Xiangya Hospital of Central South University
Sponsor class: OTHER
Collaborators: name: Second Affiliated Hospital of Nanchang University
First posted: 2024-11-22
Enrollment: 72
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients undergone endovascular aneurysm repair.

Brief summary: Intraprosthetic thrombus (IPT) formation and its progression to limb graft occlusion (LGO) are significant complications following endovascular aneurysm repair (EVAR). Morphological metrics based on preoperative CTA have limited predictive value for these complications. This study aims to assess the potential of computational fluid dynamics (CFD) in predicting IPT formation and its progression to LGO after EVAR.


Eligibility criteria: Inclusion Criteria:

1. Aged 18 and above;
2. Patients undergone endovascular aneurysm repair;
3. Signed informed consent forms, willing to receive treatments.

Exclusion Criteria:

1. inflammatory aortic aneurysm;
2. patients diagnosed with connective tissue diseases;
3. patients diagnosed with atrial fibrillation;
4. patients lacking post-operative CTA;
5. Patients who are participating in other clinical projects;
6. Patients are not suitable to participate in this study.

Primary outcomes:
measure: Degree of intraprosthetic thrombus in limb graft
timeFrame: From January 2014 to June 2024
Secondary outcomes:
measure: Disease-related complications
timeFrame: From January 2014 to June 2024
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT06670573: The Relationship Between Allergic Rhinitis, Forward Head Posture, and Anxiety Levels in Iranian Children
Official title: The Investigation of Relationship Between Allergic Rhinitis with Forward Head Posture and Anxiety in Children
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Forward Head Posture
Allergic Rhinitis (Disorder)
Keywords: Allergic Rhinitis
Forward Head Posture
Anxiety
Children
Lead sponsor: Hormozgan University of Medical Sciences
Sponsor class: OTHER
Collaborators: name: Tehran University
First posted: 2024-11-01
Enrollment: 50
Sex: ALL
Minimum age (years): 7
Maximum age (years): 12
Standard ages: CHILD
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: This is a randomized case- control that involved 50 children aged between 7 and 12 were enrolled in the Allergy-Infection Clinic at Bandar Abbas Children's Hospital, and the study took place between may to July 2024.

Brief summary: Forward head posture is a common postural issue across all age groups, often linked to the overuse of electronic devices such as computers, smartphones, and tablets, leading to poor posture in children. Allergic rhinitis is also prevalent in children, but its effects on musculoskeletal and psychological health are not well understood.

Objective: This study aimed to explore the relationship between allergic rhinitis, forward head posture, and anxiety levels in Iranian children aged 7-12 years.

Materials and Methods: Fifty children aged 7-12 were recruited from the Allergy-Infection Clinic at Bandar Abbas Children's Hospital. The participants were divided into two groups: 25 healthy children and 25 children diagnosed with allergic rhinitis. Anxiety levels were assessed using the Spence Anxiety Scale, while forward head posture was measured by analyzing photographs of the children's body profiles using AutoCAD software.


Eligibility criteria: The inclusion criteria :

1. children to be between 7 to 12 years old,
2. with and without Allergic Rhinitis,
3. body mass index below 95%
4. without asthma, cardiac diseases, neuromuscular diseases, tonsillectomy, congenital anomalies,
5. using smart devices less than 3 hours.

The exclusion criteria :

1-no consent

Primary outcomes:
measure: Forward Head Posture
timeFrame: 2 month
Secondary outcomes:
Other outcomes:
Locations:
city: Tehran
country: Iran, Islamic Republic of
facility: Tehran University
Study officials:
affiliation: Guilan University
name: Hasan Daneshmandi, Professor
role: STUDY_DIRECTOR
affiliation: Tehran University
name: Mohammad Hosein Alizade, Professor
role: STUDY_DIRECTOR
affiliation: Hormozgan University of Medical Sciences
name: Mohammad Bagher Rahmati, Associate Professor
role: STUDY_DIRECTOR
References:
Clinical trial NCT05045573: Pathological Results of Aggressive Hepatocellular Carcinomas Treated Using SIRT
Official title: Pathological Results After Downstaging of Agressive Hepatocellular Carcinoma Using 90Y-SIRT With Personalized Dosimetry
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Hepatocellular Carcinoma
Lead sponsor: University Hospital, Montpellier
Sponsor class: OTHER
First posted: 2021-09-16
Enrollment: 28
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: aggressive hepatocellular carcinomas

Brief summary: The aim of our study is to analyze pathological analysis of surgically treated aggressive hepatocellular carcinomas after radio-embolization.

The investigators aim to demonstrate that a higher dose results in better tumor response while respecting safety conditions, that is, no radiologically induced liver disease.


Eligibility criteria: Inclusion criteria:

- aggressive hepatocellular carcinomas with vascular invasion, large tumors or multifocal distribution

Exclusion criteria:

* Other treatment after SIRT (confounding effect)
* contraindications for surgery

Primary outcomes:
measure: Pathological tumor response
timeFrame: 6 months
Secondary outcomes:
measure: Rate of Healthy liver hypertrophia
timeFrame: day 1
Other outcomes:
Locations:
city: Montpellier
country: France
facility: Uhmontpellier
Study officials:
affiliation: University Hospital, Montpellier
name: BORIS GUIU, PU-PH
role: STUDY_DIRECTOR
affiliation: University Hospital, Montpellier
name: Mohamad MEERUN, intern
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00114673: A Study to Validate Cosmetic Outcome Scales Used to Rate Uneven Skin Color and Wrinkling
Official title: A Multicenter Study to Validate Cosmetic Outcome Scales Used to Assess Irregular Skin Pigmentation and Wrinkling
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Skin Wrinkling
Keywords: Uneven skin color
Wrinkles
Wrinkles and uneven skin color in the area around the eyes
Lead sponsor: Graceway Pharmaceuticals, LLC
Sponsor class: INDUSTRY
First posted: 2005-06-17
Enrollment: 48
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: DEFINED_POPULATION
Time perspective: OTHER

Brief summary: Skin chronically exposed to the sun may become damaged and then develop wrinkles and/or uneven skin color. The purpose of this research study is to evaluate a newly developed scale (grading tool) that rates wrinkles and uneven skin color. This newly developed scale will be used in future topical drug studies to measure these changes in the skin.


Eligibility criteria: Inclusion Criteria:

* At least 18 years of age

Exclusion Criteria:

* Have any disease of the skin, condition, or cosmetics around the eyes that may cause difficulty with the skin assessment using the scale to rate wrinkles and uneven skin color

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Boston
country: United States
state: Massachusetts
Study officials:
affiliation: Boston University
name: Tania J Phillips, M.D.
role: PRINCIPAL_INVESTIGATOR
References: